Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $3.92
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 30, 25 |
Daily · Wilder smoothing
| Maxim Group |
| upgrade |
| Hold |
| Buy |
| Jul 11, 23 | Brookline Capital | maintain | Buy | Buy |
| Aug 17, 22 | Maxim Group | downgrade | Buy | Hold |
| Oct 13, 21 | Brookline Capital | maintain | Buy | Buy |
| Jun 29, 21 | Litchfield Hills | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 47.54 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 69.84 | Oscillator | Neutral |
| Williams %R (14) | -38.67 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.21 (Hist 0.09) | Oscillator | Buy |
| Average Directional Index (14) | 18.43 (+DI 22.3 / -DI 21.4) | Trend | Neutral |
| EMA 20 | 3.95 | MA | Sell |
| SMA 20 | 3.84 | MA | Buy |
| EMA 50 | 4.18 | MA | Strong Sell |
| SMA 50 | 4.79 | MA | Strong Sell |
| SMA 200 | 3.26 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | ADIL | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.2x | -1.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.5x | EPS est. -2.60 | Elevated |
| Price / Book | 116.1x | 4.4x | Elevated |
| Price / Sales | — | — | n/a |
| EV / EBITDA | 0.3x | -0.7x | Discount |
| Return on equity | -1693.2% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.03 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -12.29 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 17, 26 | Young Wendy B. | director | A-Award | 25,666 @ $2.98 | $76.48K |
| Jul 16, 26 | Coastlands Capital Lp | 10 percent owner | P-Purchase | 1,233 @ $2.75 | $3.39K |
| Jul 14, 26 | Coastlands Capital Lp | 10 percent owner | P-Purchase | 2,000 @ $2.65 | $5.30K |
| Jul 10, 26 | Coastlands Capital Lp | 10 percent owner | P-Purchase | 1,700 @ $2.70 | $4.59K |
| Jul 9, 26 | Coastlands Capital Lp | 10 percent owner | P-Purchase | 10,053 @ $2.79 | $28.05K |
| Jun 29, 26 | Coastlands Capital Lp | 10 percent owner | P-Purchase | 25,000 @ $2.60 | $65.00K |
| Jun 24, 26 | Coastlands Capital Lp | 10 percent owner | 0 | — | |
| Jun 24, 26 | Coastlands Capital Lp | 10 percent owner | 3,637,818 @ $0.001 | $3.64K |
Stock news · updated daily
Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.
GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company.
Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -1.03 | -11.25 | Miss -992.2% | — |
| May 13, 2026 | -2.73 | -1.48 | Beat 45.8% | — |
| Mar 10, 2026 | -2.10 | -1.81 | Beat 13.8% | — |
| Nov 13, 2025 | -2.25 | -2.00 | Beat 11.1% | — |
| Aug 13, 2025 | -5.50 | -4.50 | Beat 18.2% | — |
| May 14, 2025 | -12.50 | -8.50 | Beat 32.0% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q/A | Oct 21, 2026 | 2026-10-20 20:25:58 | View |
| S-3/A | Oct 21, 2026 | 2026-10-20 19:53:37 | View |
| DEFA14A | Oct 16, 2026 | 2026-10-16 17:16:27 | View |
| 8-K | Oct 16, 2026 | 2026-10-16 17:15:28 | View |
| DEFA14A | Oct 5, 2026 | 2026-10-02 18:58:52 | View |
| 8-K | Oct 2, 2026 | 2026-10-02 16:16:12 | View |
| 4 | Sep 21, 2026 | 2026-09-21 19:25:34 | View |
| DEFA14A | Sep 18, 2026 | 2026-09-18 17:18:00 | View |
| 8-K | Sep 18, 2026 | 2026-09-18 16:27:15 | View |
| DEFA14A | Sep 16, 2026 | 2026-09-16 17:29:17 | View |
Proxy statement (DEF 14A) disclosures